Market Summary
USD0.66-0.01
Market Closed-1.49%
NVTA Stock Price
NVTA RSI Chart
NVTA Valuation
NVTA Price/Sales (Trailing)
NVTA Profitability
NVTA Fundamentals
NVTA Revenue
NVTA Earnings
Price Action
52 Week Range
0.633.78
(Low)(High)
Last 7 days
-14.2%
Last 30 days
-26.6%
Last 90 days
-39.9%
Trailing 12 Months
-72.9%
NVTA Financial Health
NVTA Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for NVTA
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-06-13 | Nussbaum Robert L | sold | -9,757 | 1.377 | -7,086 | chief medical officer |
2023-06-13 | Brida Thomas | sold | -9,747 | 1.377 | -7,079 | see remarks |
2023-05-16 | Wen Yafei | sold | -52,112 | 1.1993 | -43,452 | chief financial officer |
2023-05-16 | Brida Thomas | sold | -31,752 | 1.1993 | -26,476 | see remarks |
2023-05-16 | Nussbaum Robert L | sold | -31,752 | 1.1993 | -26,476 | chief medical officer |
2023-05-16 | Wen Yafei | sold | -86,599 | 1.993 | -43,452 | chief financial officer |
2023-05-16 | Knight Kenneth D. | sold | -54,486 | 1.1993 | -45,432 | chief executive officer |
2023-05-16 | WERNER ROBERT F. | sold | -25,855 | 1.1993 | -21,559 | chief accounting officer |
2023-04-27 | Osborne William H | acquired | - | - | 88,027 | - |
2023-04-27 | Crouse Geoffrey | acquired | - | - | 70,422 | - |
Which funds bought or sold NVTA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | reduced | -47.83 | -168,000 | 127,000 | -% |
2023-09-13 | CGC Financial Services, LLC | new | - | 17.00 | 17.00 | -% |
2023-09-12 | Farther Finance Advisors, LLC | new | - | 57.00 | 57.00 | -% |
2023-09-05 | Delos Wealth Advisors, LLC | unchanged | - | -17.00 | 85.00 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 0.41 | -27,900 | 147,017 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -70.2 | -297,268 | 98,790 | -% |
2023-08-16 | Nuveen Asset Management, LLC | unchanged | - | -49,975 | 259,025 | -% |
2023-08-16 | CreativeOne Wealth, LLC | added | 78.17 | 163,000 | 338,000 | 0.01% |
2023-08-16 | Sunbelt Securities, Inc. | added | 102 | 113 | 243 | -% |
2023-08-15 | CAPTRUST FINANCIAL ADVISORS | added | 1.85 | -2,288 | 13,229 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Invitae
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Aug 30, 2023 | flynn james e | 4.9% | 93,062,106 | SC 13G | |
| Feb 14, 2023 | casdin capital, llc | 3.72% | 9,038,388 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.30% | 22,587,955 | SC 13G/A | |
| Feb 03, 2023 | sumitomo mitsui trust holdings, inc. | 7.10% | 17,256,161 | SC 13G/A | |
| Jan 25, 2023 | blackrock inc. | 9.0% | 21,768,046 | SC 13G | |
| Feb 14, 2022 | casdin capital, llc | 5.39% | 12,203,669 | SC 13G/A | |
| Feb 14, 2022 | nikko asset management americas, inc. | 8.39% | 18,998,453 | SC 13G/A | |
| Feb 14, 2022 | baker bros. advisors lp | 4.4% | 9,873,488 | SC 13G/A | |
| Feb 09, 2022 | ark investment management llc | 11.80% | 26,700,813 | SC 13G/A | |
| Feb 04, 2022 | sumitomo mitsui trust holdings, inc. | 8.39% | 18,998,453 | SC 13G/A |
Recent SEC filings of Invitae
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 25, 2023 | 4 | Insider Trading | |
| Sep 22, 2023 | 8-K | Current Report | |
| Sep 14, 2023 | 3 | Insider Trading | |
| Aug 30, 2023 | SC 13G | Major Ownership Report | |
| Aug 23, 2023 | 8-K | Current Report | |
| Aug 17, 2023 | 3 | Insider Trading | |
| Aug 14, 2023 | 8-K | Current Report | |
| Aug 10, 2023 | 424B2 | Prospectus Filed | |
| Aug 10, 2023 | 424B2 | Prospectus Filed | |
| Aug 09, 2023 | EFFECT | EFFECT |
Peers (Alternatives to Invitae)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 273.3B | 56.0B | 5.43% | 9.20% | 31.46 | 4.88 | -2.31% | -31.27% |
VRTX | 90.4B | 9.5B | 0.17% | 23.71% | 26.87 | 9.51 | 13.83% | 5.33% |
REGN | 89.3B | 12.7B | 0.52% | 19.69% | 20.77 | 7.05 | -10.94% | -24.40% |
INCY | 13.1B | 3.5B | -8.00% | -12.17% | 35.8 | 3.73 | 5.81% | -61.22% |
| MID-CAP | ||||||||
NTRA | 5.2B | 931.0M | -21.23% | 3.57% | -10.07 | 5.54 | 28.69% | 11.08% |
ARWR | 2.9B | 256.2M | -4.44% | -13.77% | -15.77 | 11.15 | 2.51% | -17.66% |
| SMALL-CAP | ||||||||
VCYT | 1.6B | 328.6M | -11.64% | 35.52% | -56.17 | 4.97 | 22.46% | 40.27% |
CSTL | 442.5M | 167.5M | -11.33% | -32.98% | -4.98 | 2.64 | 52.01% | -99.69% |
CDNA | 412.7M | 309.3M | -12.49% | -52.63% | -4.91 | 1.33 | -1.76% | -21.01% |
ORGO | 325.7M | 457.3M | -6.77% | -21.02% | 32.41 | 0.71 | -0.61% | -85.93% |
CELC | 211.3M | - | -3.24% | 7.89% | -4.31 | - | - | -59.74% |
NVTA | 174.4M | 493.9M | -26.61% | -72.91% | -0.22 | 0.35 | -1.39% | 74.28% |
OPGN | 1.6M | 2.8M | 31.52% | -41.92% | -0.04 | 0.56 | -31.25% | -41.90% |
Invitae News
Returns for NVTA
Cumulative Returns on NVTA
-30.5%
7-Year Cumulative Returns
-47.6%
5-Year Cumulative Returns
-75.4%
3-Year Cumulative Returns
Risks for NVTA
What is the probability of a big loss on NVTA?
100%
Probability that Invitae stock will be more than 20% underwater in next one year
100%
Probability that Invitae stock will be more than 30% underwater in next one year.
86.5%
Probability that Invitae stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does NVTA drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Invitae was unfortunately bought at previous high price.
Drawdowns
Financials for Invitae
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -3.2% | 493,878,000 | 509,968,000 | 516,303,000 | 519,970,000 | 500,829,000 | 480,519,000 | 460,449,000 | 434,759,000 | 389,092,000 | 318,971,000 | 279,598,000 | 245,452,000 | 233,235,000 | 240,519,000 | 216,824,000 | 195,895,000 | 176,750,000 | 160,581,000 | 147,699,000 | 127,742,000 | 108,524,000 |
| S&GA Expenses | -8.9% | 185,230,000 | 203,247,000 | 218,881,000 | 234,291,000 | 240,599,000 | 234,814,000 | 225,910,000 | 212,582,000 | 194,881,000 | 177,437,000 | 168,317,000 | 154,015,000 | 148,905,000 | 140,164,000 | 122,237,000 | 106,868,000 | 91,769,000 | 79,697,000 | 74,428,000 | 71,301,000 | 66,956,000 |
| R&D Expenses | -15.3% | 284,508,000 | 335,830,000 | 402,088,000 | 462,323,000 | 472,657,000 | 463,965,000 | 416,087,000 | 356,495,000 | 296,786,000 | 265,295,000 | 240,605,000 | 219,712,000 | 228,861,000 | 179,200,000 | 141,526,000 | 106,817,000 | 75,642,000 | 66,124,000 | 63,496,000 | 60,531,000 | 56,257,000 |
| EBITDA | 100.0% | - | -2,923,369,000 | -2,952,379,000 | -3,074,270,000 | -2,995,039,000 | -400,734,000 | -285,491,000 | -456,477,000 | -365,816,000 | -649,759,000 | -645,454,000 | -402,508,000 | -394,542,000 | -286,534,000 | -231,797,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -5.73 | -5.72 | -5.91 | -5.98 | -0.83 | -0.62 | -1.05 | -0.94 | -2.04 | -2.31 | -1.64 | -1.69 | -1.19 | -1.07 | - | - | - | - | - | - |
| Interest Expenses | -14.7% | 46,259,000 | 54,258,000 | 56,747,000 | 56,180,000 | 56,104,000 | 55,492,000 | 49,900,000 | 48,391,000 | 40,630,000 | 32,708,000 | 29,766,000 | 22,594,000 | 19,119,000 | 15,755,000 | 12,412,000 | 9,165,000 | 8,176,000 | 7,846,000 | 7,030,000 | 6,064,000 | 5,348,000 |
| Earnings Before Taxes | 74.2% | -807,972,000 | -3,127,561,000 | -3,151,197,000 | -3,258,800,000 | -3,160,600,000 | -516,350,000 | -415,863,000 | -546,928,000 | -445,806,000 | -732,035,000 | -714,270,000 | -453,137,000 | -437,642,000 | -321,265,000 | -260,415,000 | -230,232,000 | -155,986,666 | - | -132,155,000 | -135,249,000 | -135,686,000 |
| EBT Margin | 100.0% | - | -6.13 | -6.10 | -6.27 | -6.31 | -1.07 | -0.90 | -1.26 | -1.15 | -2.29 | -2.55 | -1.85 | -1.88 | -1.34 | -1.20 | - | - | - | - | - | - |
| Net Income | 74.3% | -799,667,000 | -3,116,617,000 | -3,106,293,000 | -3,211,600,000 | -3,108,620,000 | -451,373,000 | -379,006,000 | -408,220,000 | -312,946,000 | -613,135,000 | -602,170,000 | -444,737,000 | -420,542,000 | -302,815,000 | -241,965,000 | -194,901,000 | -147,917,000 | -130,912,000 | -129,355,000 | -140,007,000 | -135,686,000 |
| Net Income Margin | 100.0% | - | -6.11 | -6.02 | -6.18 | -6.21 | -0.94 | -0.82 | -0.94 | -0.80 | -1.92 | -2.15 | -1.81 | -1.80 | -1.26 | -1.12 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -413,601,000 | -546,270,000 | -654,424,000 | -694,738,000 | -686,975,000 | -614,535,000 | -541,886,000 | -426,758,000 | -351,127,000 | -321,367,000 | -252,694,000 | -228,793,000 | -200,161,000 | -165,100,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -10.0% | 1,523 | 1,692 | 1,954 | 2,026 | 2,291 | 4,768 | 4,920 | 5,071 | 4,995 | 3,873 | 3,430 | 913 | 970 | 791 | 782 | 790 | 503 | 476 | 283 | 284 | 239 |
| Current Assets | -10.5% | 451 | 504 | 693 | 730 | 894 | 1,031 | 1,179 | 1,366 | 1,644 | 780 | 454 | 415 | 471 | 357 | 442 | 509 | 288 | 321 | 165 | 167 | 123 |
| Cash Equivalents | 38.2% | 223 | 161 | 257 | 217 | 304 | 325 | 934 | 922 | 1,108 | 204 | 131 | 113 | 175 | 97.00 | 158 | 473 | 253 | 258 | 118 | 106 | 54.00 |
| Inventory | 9.1% | 21.00 | 19.00 | 30.00 | 30.00 | 49.00 | 43.00 | 34.00 | 31.00 | 30.00 | 31.00 | 32.00 | - | - | - | 7.00 | - | - | - | - | - | - |
| Net PPE | -3.5% | 92.00 | 95.00 | 109 | 114 | 133 | 130 | 115 | 101 | 83.00 | 73.00 | 66.00 | 46.00 | 43.00 | 41.00 | 38.00 | 32.00 | 29.00 | 26.00 | 23.00 | 29.00 | 29.00 |
| Goodwill | - | - | - | - | - | - | 2,283 | 2,283 | 222 | 2,061 | 1,926 | 1,864 | 211 | 211 | 51.00 | 127 | 100 | 26.00 | 50.00 | 50.00 | 47.00 | - |
| Liabilities | -0.3% | 1,724 | 1,728 | 1,852 | 1,867 | 1,905 | 1,924 | 1,941 | 1,964 | 2,341 | 1,497 | 1,454 | 497 | 506 | 465 | 402 | 387 | 161 | 160 | 121 | 105 | 100 |
| Current Liabilities | -20.1% | 152 | 190 | 108 | 113 | 139 | 168 | 144 | 156 | 134 | 146 | 122 | 101 | 127 | 121 | 82.00 | 69.00 | 40.00 | 42.00 | 36.00 | 43.00 | 33.00 |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 75.00 | 75.00 | 74.00 | 50.00 | 56.00 |
| Shareholder's Equity | -Infinity% | -200 | - | 102 | 159 | 386 | 2,844 | 2,978 | 3,107 | 2,654 | 2,376 | 1,976 | 417 | 464 | 326 | 380 | 404 | 342 | 316 | 162 | 179 | 139 |
| Retained Earnings | -4.1% | -5,227 | -5,021 | -4,829 | -4,729 | -4,428 | -1,904 | -1,722 | -1,517 | -1,319 | -1,453 | -1,360 | -1,126 | -1,023 | -857 | -758 | -681 | -603 | -554 | -516 | -486 | -455 |
| Additional Paid-In Capital | 0.7% | 5,018 | 4,985 | 4,931 | 4,889 | 4,815 | 4,749 | 4,701 | 4,624 | 3,973 | 3,830 | 3,337 | 1,543 | 1,487 | 1,182 | 1,138 | 1,086 | 945 | 871 | 679 | 666 | 594 |
| Shares Outstanding | 5.6% | 264 | 250 | 246 | 238 | 232 | 228 | 228 | 218 | 204 | 194 | 186 | 132 | 129 | 100 | 99.00 | 96.00 | 91.00 | 79.00 | 67.00 | 64.00 | 61.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 21.0% | -300 | -379 | -492 | -586 | -623 | -617 | -559 | -497 | -394 | -325 | -298 | -232 | -206 | -179 | -145 | -113 | -94.64 | -87.68 | -92.22 | -108 | -114 |
| Share Based Compensation | -14.7% | 155 | 182 | 199 | 213 | 178 | 168 | 180 | 188 | 184 | 188 | 159 | 130 | 138 | 100 | 76.00 | 53.00 | 30.00 | 22.00 | 21.00 | 21.00 | 20.00 |
| Cashflow From Investing | 2.0% | 356 | 349 | -174 | -126 | -190 | -379 | -204 | -686 | -672 | -674 | -400 | -358 | -370 | -261 | -280 | 2.00 | 25.00 | -1.72 | 36.00 | 32.00 | 6.00 |
| Cashflow From Financing | -2.2% | -135 | -133 | 2.00 | 8.00 | 9.00 | 1,129 | 1,566 | 2,003 | 2,010 | 1,109 | 673 | 231 | 499 | 279 | 465 | 478 | 269 | 324 | 157 | 143 | 130 |
NVTA Income Statement
2023-06-30Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Total revenue | $ 120,532 | $ 136,622 | $ 237,888 | $ 260,313 |
| Operating expenses: | ||||
| Cost of revenue | 87,474 | 110,340 | 175,916 | 207,456 |
| Research and development | 63,824 | 115,146 | 125,802 | 243,382 |
| Selling and marketing | 44,732 | 62,749 | 89,242 | 122,893 |
| General and administrative | 69,966 | 50,854 | 115,207 | 102,282 |
| Goodwill and IPR&D impairment | 0 | 2,313,047 | 0 | 2,313,047 |
| Restructuring and other costs | 80,998 | 4,817 | 133,554 | 4,817 |
| Total operating expenses | 346,994 | 2,656,953 | 639,721 | 2,993,877 |
| Loss from operations | (226,462) | (2,520,331) | (401,833) | (2,733,564) |
| Other income (expense), net: | ||||
| Loss on extinguishment of debt, net | 0 | 0 | (10,822) | 0 |
| Debt issuance costs | 0 | 0 | (19,859) | 0 |
| Change in fair value of convertible senior secured notes | 20,619 | 0 | 38,923 | 0 |
| Change in fair value of acquisition-related liabilities | 49 | 6,190 | 267 | 16,193 |
| Other income, net | 4,379 | 1,136 | 10,262 | 1,572 |
| Total other income, net | 25,047 | 7,326 | 18,771 | 17,765 |
| Interest expense | (6,020) | (14,019) | (17,516) | (28,004) |
| Net loss before taxes | (207,435) | (2,527,024) | (400,578) | (2,743,803) |
| Income tax benefit | 924 | 3,563 | 1,884 | 38,483 |
| Net loss | $ (206,511) | $ (2,523,461) | $ (398,694) | $ (2,705,320) |
| Net (loss) income per share, basic (in dollars per share) | $ (0.78) | $ (10.87) | $ (1.55) | $ (11.75) |
| Net (loss) income per share, diluted (in dollars per share) | $ (0.78) | $ (10.87) | $ (1.55) | $ (11.75) |
| Shares used in computing net loss per share, basic | 263,836 | 232,117 | 256,910 | 230,304 |
| Shares used in computing net loss per share, diluted | 263,836 | 232,117 | 256,910 | 230,304 |
| Test revenue | ||||
| Revenue: | ||||
| Total revenue | $ 115,943 | $ 133,182 | $ 228,566 | $ 252,679 |
| Other revenue | ||||
| Revenue: | ||||
| Total revenue | $ 4,589 | $ 3,440 | $ 9,322 | $ 7,634 |
NVTA Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 222,758 | $ 257,489 |
| Marketable securities | 102,379 | 289,611 |
| Accounts receivable | 85,610 | 96,148 |
| Inventory | 20,814 | 30,386 |
| Prepaid expenses and other current assets | 19,664 | 19,496 |
| Total current assets | 451,225 | 693,130 |
| Property and equipment, net | 92,091 | 108,723 |
| Operating lease assets | 74,718 | 106,563 |
| Restricted cash | 10,508 | 10,030 |
| Intangible assets, net | 873,924 | 1,012,549 |
| Other assets | 20,573 | 23,121 |
| Total assets | 1,523,039 | 1,954,116 |
| Current liabilities: | ||
| Accounts payable | 23,067 | 13,984 |
| Accrued liabilities | 107,951 | 74,388 |
| Operating lease obligations | 16,436 | 14,600 |
| Finance lease obligations | 4,514 | 5,121 |
| Total current liabilities | 151,968 | 108,093 |
| Operating lease obligations, net of current portion | 139,630 | 134,386 |
| Finance lease obligations, net of current portion | 1,604 | 3,780 |
| Debt | 0 | 122,333 |
| Convertible senior notes, net | 1,170,611 | 1,470,783 |
| Convertible senior secured notes (at fair value) | 249,571 | 0 |
| Deferred tax liability | 6,200 | 8,130 |
| Other long-term liabilities | 4,241 | 4,775 |
| Total liabilities | 1,723,825 | 1,852,280 |
| Commitments and contingencies | ||
| Stockholders’ (deficit) equity: | ||
| Common stock | 27 | 25 |
| Accumulated other comprehensive income (loss) | 8,910 | (80) |
| Additional paid-in capital | 5,018,112 | 4,931,032 |
| Accumulated deficit | (5,227,835) | (4,829,141) |
| Total stockholders’ (deficit) equity | (200,786) | 101,836 |
| Total liabilities and stockholders’ (deficit) equity | $ 1,523,039 | $ 1,954,116 |
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.